Core Viewpoint - RxSight, Inc. is under investigation for potential violations of federal securities laws following a significant decline in its stock price due to revenue forecast cuts related to a slowdown in product utilization [1][4][5]. Company Overview - RxSight specializes in manufacturing and selling light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [2]. Financial Performance - The company previously reported strong sales for its LAL and Light Delivery Device (LDD), but began experiencing a slowdown in LAL utilization noted in 2024 [3]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38% from $26.12 to $16.21 per share [4]. - A further revenue forecast cut occurred on July 8, 2025, attributed to slower LAL utilization, resulting in another 38% decline in stock price from $12.79 to $7.95 per share [5].

Core Viewpoint - Rosen Law Firm has announced the filing of a class action lawsuit on behalf of purchasers of Centene Corporation securities between December 12, 2024, and June 30, 2025, alleging misleading statements regarding the company's financial performance and enrollment rates [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that during the Class Period, Centene's management provided investors with overly positive information regarding expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year [5]. - Defendants allegedly made confident statements about Centene's enrollment and morbidity rates, as well as strong retention rates in its Medicare business, while concealing material adverse facts about the true state of these metrics [5]. Group 2: Participation Information - Investors who purchased Centene common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

SAN DIEGO, July 18, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Neogen Corporation (NASDAQ: NEOG) securities between January 6, 2023 and June 3, 2025. Neogen is a food safety company that manufactures and markets products and services dedicated to food and animal safety.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Inve ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Jasper Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On July 7, 2025, Jasper Therapeutics released updated data from its BEACON Phase 1b/2a study of briquilimab, indicating issues with a specific drug product lot that affected results in certain patient cohorts [3] - The stock price of Jasper Therapeutics fell by $3.73 per share, or 55.1%, closing at $3.04 per share following the announcement of the study results [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving WPP plc and its officers or directors [1] Financial Performance - On July 8, 2025, WPP reduced its 2025 guidance for like-for-like revenue less pass-through costs to a decline of 3% to 5% and anticipated a year-on-year decline in headline operating profit margin of 50 to 175 basis points, excluding foreign exchange effects [3] - WPP reported a deterioration in performance as the second quarter progressed, attributing this to a challenging economic backdrop and expected continued macro uncertainty affecting client spending and weaker net new business than initially anticipated [3] - Following the announcement, WPP's American Depositary Receipt (ADR) price fell by $6.48, or 18.09%, closing at $29.34 per ADR on July 9, 2025 [3]

NEW YORK, July 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Reckitt Benckiser Group plc ("Reckitt Benckiser Group plc" or the "Company") (OTC PINK: RBGLY) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Reckitt Benckiser Group plc investors who were adversely affected by alleged securities fraud between January 13, 2021 and July 28, 2024. Follow the link below to get more information and be contacted by a member of our team:http ...

LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Centene Corporation (“Centene” or the “Company”) (NYSE: CNC) securities between December 12, 2024 to June 30, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR CENTENE INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO ...

RADNOR, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Centene Corporation (“Centene”) (NYSE: CNC) on behalf of those who purchased or otherwise acquired Centene securities between December 12, 2024, and June 30, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is September 8, 2025. ...

Core Viewpoint - A class action lawsuit has been filed against Broadmark Realty Capital Inc. and Ready Capital Corporation for alleged violations of federal securities laws related to their merger [1][2]. Group 1: Lawsuit Details - The lawsuit seeks damages for investors who held Broadmark common stock as of May 30, 2023, the date of the merger with Ready Capital [2]. - The complaint alleges that the proxy statement soliciting shareholder support for the merger contained false or misleading statements and failed to disclose significant financial distress among borrowers in Ready Capital's portfolio due to high interest rates [3]. - It is claimed that an oversupply of multifamily properties limited the ability of Ready Capital borrowers to raise rents to cover growing debt costs [3]. - A major development project acquired during the merger, valued at approximately $500 million, faced severe setbacks including cost overruns and construction delays, which were not disclosed [3]. - As a result of these issues, Ready Capital's expected credit losses and financial projections were materially understated [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Broadmark have until July 28, 2025, to request to be appointed as lead plaintiff in the class action [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions for investors [6].

SAN DIEGO, July 16, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, announces that a class action lawsuit has commenced on behalf of investors of Fortrea Holdings Inc. (NASDAQ: FTRE). The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to co ...